Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $52.7 million, down 1.23% from fiscal 2024. In the quarter to June 2026, revenue grew 27.1%, EPS grew 2,281.0% and free cash flow fell 94.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow PLX
Protalix BioTherapeutics, Inc. (PLX) EV/Sales
As of 16 October 2026, Protalix BioTherapeutics, Inc. (PLX) trades at a EV/Sales of 2.3×. Over the past ten years it has ranged from −105× (May 2015) to 65.3× (January 2015); the current reading is higher than 62% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.5× | 8.63% |
| FY2024 | 2.3× | 51.57% |
| FY2023 | 1.5× | (1.12%) |
| FY2022 | 1.5× | 128.28% |
| FY2021 | 0.7× | (41.61%) |
| FY2020 | 1.1× | (23.78%) |
| FY2019 | 1.5× | (8.14%) |
| FY2018 | 1.6× | (59.87%) |
| FY2017 | 4.1× | — |
| FY2016 | −0.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.0× | 10.47% |
| Mar 2026 | 1.9× | (25.09%) |
| Dec 2025 | 2.5× | (8.22%) |
| Sep 2025 | 2.7× | 61.95% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IFRX InflaRx N.V. compare | −1,061× |
| KROS Keros Therapeutics, Inc. compare | −1.4× |
| PYXS Pyxis Oncology, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| MGNX MacroGenics, Inc. compare | 0.2× |
| PLX Protalix BioTherapeutics, Inc. | 2.3× |
| ALEC Alector, Inc. compare | 3.6× |
| CAMP CAMP4 Therapeutics Corporation compare | 22.9× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)